

Bronson Healthcare

2019-20 (Two-Year) Antibiotic Activity Summary

Antibiogram

Bronson South Haven Hospital Inpatients and Emergency Department

Percent of strains susceptible:

	No. Tested	Ampicillin/Sulbactam	Piperacillin/tazobactam	Aztreonam	Cefazolin	Cefoxitin	Ceftriaxone	Cefepime	Meropenem	Gentamicin	Tobramycin	Amikacin	Levofloxacin	Sulfa/Trimethoprim	Nitrofurantoin	Tetracycline
Gram Negative Enteric Bacteria																
<i>Escherichia coli</i>	455	63	98	96	94	95	95	96	100	92	93	100	86	73	95	76
<i>Klebsiella pneumoniae</i>	65	88	92	97	95	97	97	97	100	95	95	100	95	97	40	85
<i>Proteus mirabilis</i>	43	93	100	98	98	98	100	100	100	98	98	100	88	81	R	R

	No. Tested	Penicillin/ampicillin	Erythromycin	Clindamycin	Levofloxacin	Vancomycin	Tetracycline	Linezolid
Streptococci								
<i>Streptococcus agalactiae</i>	36	100	36	94	100	100	R	100

	No. Tested	Penicillin/ampicillin	Oxacillin/nafcillin	Erythromycin	Clindamycin	Gentamicin	Levofloxacin	Sulfa/Trimethoprim	Vancomycin	Rifampin*	Tetracycline	Minocycline	Linezolid	Nitrofurantoin
Staphylococcus aureus														
<i>Staphylococcus aureus</i>	75	R	79	36	89	96	60	97	100	100	92	100	100	99

*Rifampin should be used only in combination with another agent

	No. Tested	Penicillin/ampicillin	Levofloxacin	Vancomycin	Linezolid	Nitrofurantoin	Gentamicin Synergy	Streptomycin Synergy
Enterococci								
<i>Enterococcus faecalis</i>	50	100	82	100	100	98	90	89

R denotes intrinsic resistance

Dosing recommendations are generalized; dosing should be optimized for each patient.

Adam Warner, PharmD
Antimicrobial Stewardship Pharmacist
(269) 341-6230
warnera@bronsonhq.org

Richard A. Van Enk, Ph.D.
Epidemiologist
(269) 341-6316
vanenkr@bronsonhq.org

Eric Parnelle
Laboratory Supervisor
(269)341-8845
parnelle@bronsonhq.org